Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Diagnosis and initial management of cyanotic heart disease in the newborn

INTRODUCTION

Cyanotic lesions comprise approximately one-third of potentially fatal forms of congenital heart disease (CHD) [1,2]. Early recognition, emergent stabilization, and transport to an appropriate cardiac care center are critically important in the outcome of newborns with these lesions.

The evaluation and initial management of cyanotic CHD in the newborn are presented here. The causes of neonatal cyanotic cardiac lesions are discussed separately. (See "Cardiac causes of cyanosis in the newborn".)

PRENATAL DIAGNOSIS

Prenatal sonograms often identify structural malformations including CHD, diaphragmatic hernia, and congenital cystic adenomatoid malformation; however, the sensitivity of CHD detection is highly variable depending on operator expertise, gestational age, fetal position, and type of defect. As a result, prenatal sonography will miss some patients with cyanotic CHD. (See "Congenital heart disease (CHD) in the newborn: Presentation and screening for critical CHD", section on 'Variability of prenatal ultrasound' and "Fetal cardiac abnormalities: Screening, evaluation, and pregnancy management".)

POSTNATAL DIAGNOSIS

In affected neonates who are not identified by prenatal sonography, a clinical diagnosis of cyanotic congenital heart disease (CHD) is based on history, physical findings, chest radiography, and hyperoxia test. The diagnosis is confirmed by echocardiography.

Central cyanosis caused by reduced arterial oxygen saturation is generally perceptible when the reduced hemoglobin level exceeds 3 g/dL (figure 1) [3]. It can result from several different pathologic mechanisms that are caused by cardiac disorders, pulmonary abnormalities, or hemoglobinopathies (table 1) [3]. (See "Cardiac causes of cyanosis in the newborn", section on 'Etiology' and "Overview of cyanosis in the newborn", section on 'Hemoglobin concentration' and "Overview of cyanosis in the newborn", section on 'Central cyanosis'.)

                             

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Oct 2014. | This topic last updated: Jun 17, 2014.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Duff DF, McNamara DG. History and physical examination of the cardiovascular system. In: The science and practice of pediatric cardiology, Garson A Jr, Bricker TM, Fisher DJ, Neish SR (Eds), Williams and Wilkins, Baltimore 1998. p.693.
  2. Report of the New England Regional Infant Cardiac Program. Pediatrics 1980; 65:375.
  3. Lees MH. Cyanosis of the newborn infant. Recognition and clinical evaluation. J Pediatr 1970; 77:484.
  4. Zuberbuhler JR. Tetralogy of Fallot. In: Heart disease in infants, children, and adolescents, 5th ed, Emmanouilides GC, Riemenschneider TA, Allen HD, Getgesell HP (Eds), Williams and Wilkins, Baltimore 1995. p.998.
  5. Mair DD, Edwards WD, Julsrud PR, et al. Truncus arteriosus. In: Heart disease in infants, children, and adolescents, 5th ed, Emmanouilides GC, Riemenschneider TA, Allen HD, Getgesell HP (Eds), Williams and Wilkins, Baltimore 1995. p.1026.
  6. Jones RW, Baumer JH, Joseph MC, Shinebourne EA. Arterial oxygen tension and response to oxygen breathing in differential diagnosis of congenital heart disease in infancy. Arch Dis Child 1976; 51:667.
  7. Donofrio MT, Moon-Grady AJ, Hornberger LK, et al. Diagnosis and treatment of fetal cardiac disease: a scientific statement from the American Heart Association. Circulation 2014; 129:2183.
  8. Lewis AB, Freed MD, Heymann MA, et al. Side effects of therapy with prostaglandin E1 in infants with critical congenital heart disease. Circulation 1981; 64:893.
  9. Marino BS, Bird GL, Wernovsky G. Diagnosis and management of the newborn with suspected congenital heart disease. Clin Perinatol 2001; 28:91.
  10. Cheatham JP. The transcatheter management of the neonate and infant with pulmonary atresia and intact ventricular septum. J Interven Cardiol 1998; 11:363.
  11. Fletcher SE, Cheatham JP, Bolam DL. Primary transcatheter treatment of congenital pulmonary arteriovenous malformation causing cyanosis of the newborn. Catheter Cardiovasc Interv 2000; 50:48.
  12. Browning Carmo KA, Barr P, West M, et al. Transporting newborn infants with suspected duct dependent congenital heart disease on low-dose prostaglandin E1 without routine mechanical ventilation. Arch Dis Child Fetal Neonatal Ed 2007; 92:F117.